Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
TOKYO and STAMFORD, Conn., Oct. 17, 2018 /PRNewswire/ -- Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD "Purdue Pharma") today announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders. Topline results reported today are the primary and key secondary outcomes of the study from the six-month, placebo-controlled treatment period; the study is ongoing to 12 months. Eisai and Purdue Pharma plan to present full results from SUNRISE 2 at upcoming medical meetings in 2019.
SUNRISE 2 enrolled more than 900 adult patients (18 to 88 years of age) with insomnia disorder, characterized by difficulty falling asleep and/or staying asleep. The study met the pre-specified primary and key secondary efficacy objectives assessed by patient self-reports (sleep diaries). At the end of the six-month, placebo-controlled treatment period, lemborexant 5 mg and 10 mg provided statistically significant improvement in subjective sleep onset latency compared to placebo, the study's primary endpoint. Lemborexant 5 mg and 10 mg also provided statistically significant improvement in sleep maintenance variables of subjective sleep efficiency and subjective wake after sleep onset compared to placebo, which were the study's key secondary endpoints. The most common adverse events (AEs), greater than 5 percent in either lemborexant treatment arm and greater than placebo, were somnolence, headache, and influenza. Overall discontinuation rates due to AEs were comparable between placebo and lemborexant 5 mg, and higher for lemborexant 10 mg.
"As a clinician and researcher treating patients with insomnia and other sleep-wake disorders for 30 years, for me, successful treatment means that patients fall asleep fast, sleep well, and wake well, without functional impairment, or loss of effect over time," said Russell Rosenberg, PhD, D.ABSM, a Principal Investigator in the lemborexant studies and former Chairman of the Board of the National Sleep Foundation. "The results of SUNRISE 2 are particularly encouraging for the many patients who suffer from chronic insomnia."
The results of SUNRISE 2 build on a growing body of knowledge supporting the development of lemborexant, including SUNRISE 1, a recently completed Phase 3 study of lemborexant 5 mg and 10 mg versus placebo, that included a superiority comparison to zolpidem tartrate extended release (zolpidem ER) as a secondary endpoint, as well as key safety studies.
"Our aspiration for lemborexant is to bring to the millions of patients suffering from insomnia and other sleep-wake disorders an agent for sleep-wake regulation that improves their ability to fall asleep and stay asleep, and maintains efficacy over time," said Lynn Kramer, MD, Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. "In SUNRISE 2, lemborexant improved both time to sleep onset as well as sleep maintenance over a six-month period. With these results, we now look forward to proceeding with regulatory submissions for lemborexant to bring to patients a long-term treatment option for treating the sleep-wake disorder, insomnia."
Lemborexant acts on the orexin neurotransmitter system and is believed to regulate sleep and wake by dampening wakefulness without impeding the ability to awaken to external stimuli.
"We understand the importance of sleep-wake regulation to overall health and patient outcomes and, alongside our collaboration partner, Eisai, look forward to continued research as part of our commitment to a variety of patient populations with sleep-wake disorders," said Marcelo Bigal, MD, PhD, Chief Medical Officer, Purdue Pharma.
Discovered by Eisai, lemborexant is being jointly developed by Eisai and Purdue Pharma. Information about ongoing clinical studies is available at clinicaltrials.gov.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully complete clinical development or gain health authority approval.
1. About LemborexantLemborexant, an investigational dual orexin receptor
antagonist, is Eisai's in-house discovered and developed small molecule
compound that inhibits orexin neurotransmission, or signaling, by binding
competitively to two subtypes of orexin receptors (orexin receptor 1 and
2). In individuals with sleep-wake disorders, it is possible that the
orexin system that regulates wakefulness is not functioning normally.
During normal periods of sleep, orexin system activity is suppressed,
suggesting that it is possible to purposefully counteract inappropriate
wakefulness and facilitate the initiation and maintenance of sleep.Eisai
and Purdue Pharma are investigating lemborexant as a potential treatment
option for insomnia and other sleep-wake disorders. A Phase 2 clinical
study of lemborexant in patients with irregular sleep-wake rhythm
disorder (ISWRD) and mild to moderate Alzheimer's dementia is underway.
2. About Study 303(1)A 12-month multicenter, global, randomized, controlled,
double-blind, parallel group study of 971 male or female adult
participants (18 to 88 years of age) with insomnia disorder, including a
screening, a 54-week treatment period and a two-week follow-up period.
All patients received lemborexant for at least six months during the
study. Lemborexant 5 mg, 10 mg or matching placebo was taken orally in
tablet form at home each night immediately before the patient intended to
try to sleep for six months of the study. The primary outcome measure was
mean change from baseline in Subjective Sleep Onset Latency (sSOL)
compared to placebo after six months of placebo-controlled treatment. Key
secondary outcome measures were mean change from baseline in Subjective
Sleep Efficiency (sSE) and Subjective Wake after Sleep Onset (sWASO)
compared to placebo after six months of placebo-controlled treatment.
3. About Sleep DisordersPopulation studies show that sleep disorders affect
many more people worldwide than previously thought.(2 )Insomnia disorder
is characterized by difficulty falling sleep, staying asleep or both,
despite an adequate opportunity to sleep, that can lead to daytime
consequences such as fatigue, difficulty concentrating and
irritability.(3)(,4) Insomnia disorder is the most common sleep disorder,
with persistent insomnia symptoms experienced by approximately 10 percent
of the adult population.(2,3)Sleeping well is essential for good health,
including brain health. Poor sleep is associated with a wide range of
health consequences, including an increased risk of hypertension,
accidental injury, diabetes, obesity, depression, heart attack, stroke
and dementia, as well as adverse effects on mood and
behavior.(4,5)Experimental studies in animals and humans provide evidence
of associations between sleep and disease risk factors, diseases and
mortality.(2,6) Studies suggest an optimal sleep duration between seven
and eight hours.(2,6) Women are 1.4 times more likely than men to suffer
from insomnia.(7)Older adults also have higher prevalence of insomnia;
aging is often accompanied by changes in sleep patterns, including
disrupted sleep, frequent waking and early waking, that can lead to less
sleep time.(8)
4. About Eisai Co., LtdEisai Co., Ltd. is a leading global research and
development-based pharmaceutical company headquartered in Japan. We
define our corporate mission as "giving first thought to patients and
their families and to increasing the benefits health care provides,"
which we call our human health care (hhc) philosophy. With over 10,000
employees working across our global network of R&D facilities,
manufacturing sites and marketing subsidiaries, we strive to realize our
hhc philosophy by delivering innovative products in various therapeutic
areas with high unmet medical needs, including Neurology and Oncology.
Furthermore, we invest and participate in several partnership-based
initiatives to improve access to medicines in developing and emerging
countries.For more information about Eisai Co., Ltd., please visit
www.eisai.com.
5. About Purdue Pharma L.P.Purdue Pharma L.P. develops and provides
prescription medicines that meet the evolving needs of healthcare
professionals, patients, and caregivers. We were founded by physicians
and we are currently led by a physician. Beyond our efforts to provide
quality medications, Purdue is committed to supporting national, regional
and local collaborations to drive innovations in patient care. Privately
held, Purdue is pursuing a pipeline of new medications and technologies
through internal research & development and strategic industry
partnerships. For more information, please visit www.purduepharma.com.
References
(1) Eisai Inc. Long-term study of lemborexant in insomnia disorder (E2006-G000-303). Available from https://clinicaltrials.gov/ct2/show/NCT02952820. NLM identifier: NCT02952820.
(2) Ferrie JE, et al. Sleep epidemiology - a rapidly growing field. Int J Epidemiol. 2011;40(6):1431-1437.
(3) Ohayon MM, et al. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6(2):97-111.
(4) Institute of Medicine. Sleep disorders and sleep deprivation: An unmet public health problem. Washington, DC: National Academies Press. 2006.
(5) Pase MP, Himali JJ, Grima NA, et al. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017;89(12):1244-1250.
(6) Trenell MI, et al. Sleep and metabolic control: waking to a problem? Clin Exp Pharmacol Physiol. 2007;34:1-9.
(7) Zhang B, Wing, YK. Sex differences in insomnia: a meta-analysis. Sleep. 2006;29(1):85-93.
(8) Ohayon MM, et al. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004;27:1255-1273.
Contacts:
Eisai Co., Ltd.
Purdue Pharma L.P.
Michele Randazzo
Danielle Lewis
+1-201-746-2979
+1-203-588-7653
michele_randazzo@eisai.com
danielle.lewis@pharma.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/eisai-and-purdue-pharma-announce-positive-topline-results-of-sunrise-2-the-second-phase-3-pivotal-study-of-lemborexant-300732720.html
SOURCE Eisai Co., Ltd.
